Ropeginterferon alfa-2b was moved to preferred status for patients with high- and low-risk polycythemia vera in a recent update to the National Comprehensive Cancer Network (NCCN) Clinical Practice ...
While taking testosterone-based HRT, your doctor will monitor your bloodwork for signs of polycythemia. If found, several treatment options are available. Testosterone is responsible for many body ...
Two years after receiving FDA approval, Besremi is a preferred treatment option in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Besremi (ropeginterferon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback